Full-Time

Manager - Billing & Collections

Posted on 1/6/2026

ENOVIS

ENOVIS

1,001-5,000 employees

Global medical technology company; orthopedic solutions

No salary listed

No H1B Sponsorship

Lewisville, TX, USA

In Person

Travel up to 10% of the time; domestic and international travel may be required (1–5 days per trip).

Category
Accounting (1)
Requirements
  • Minimum of 6 years of Revenue Cycle Management experience required.
  • Previous experience managing people required.
  • Minimum of 3 years of experience managing an outsource billing/collections vendor required.
  • Experience with complex claims processing and/or auditing experience in the health insurance industry or medical health care delivery system required.
  • Proficiency in processing/auditing claims for Medicare, Medicaid, and commercial plans required.
  • Knowledge of CMS requirements regarding claims processing, specifically DMEPOS claim processing rules and regulations, required.
  • Bachelor’s Degree in Accounting, Finance, Business Administration, or related field equivalent required.
  • Experience may be considered in lieu of degree.
  • Must be able to travel up to 10% of the time; both domestic and international travel may be required.
  • Typical work-related travel assignments range 1-5 days, and as such overnight, out-of-town stays are required.
  • Typical office environment.
  • Physical Demands: May occasionally lift up to 10 pounds. Routinely uses standard office equipment such as computers, keyboard, phone, print. Required to talk and hear. Must be able to sit and stand for extended periods of time and use hands and fingers to handle or feel, and to manipulate keys on a keyboard and operate portable input devices (e.g., smart phone, mouse). May occasionally reach with hands and arms. Must have the ability to look at a computer screen for extended periods of time.
Responsibilities
  • Achieves assigned targets for cash collections and unapplied cash reduction.
  • Manages offshore vendor performance for end-to-end Revenue Cycle Management (RCM) services.
  • Directs the operations of the billing, collections, and cash applications teams, including denial follow-up, aged accounts receivables, and cash posting activities.
  • Plans and directs patient insurance documentation, billing and collections, and account reconciliation to ensure accurate billing and efficient account collection.
  • Partners with RCM Leadership coordinate and resolve difficulties within the department by implementing process changes and/or leading process improvement initiatives, reviewing and defining problems, suggesting procedural changes when necessary, and suggesting courses of action.
  • Manages the review and resolution of payment variances and credit balance processes.
  • Manages the number of electronic 835 payers and ensures they are set up to post electronically to the patient accounting system.
  • Manages the number of payments processed by the bank and transferred via lockbox for posting.
  • Ensures accurate denial follow-up and cash posting.
  • Submits claims to proper insurance entities and follows up on any issues.
  • Partners with Director to act as a liaison between the Finance Team, the RCM AR Team, the bank, and payment processing merchants regarding banking and accounting for the lockbox, payments, and refund checks.
  • Compiles, reviews, and evaluates required documentation specific to government and commercial payors.
  • Coordinates with various resources, contacts, and systems to obtain, verify and/or submit data.
  • Ensures documents for submission are accurate, legal, and in compliance with the Company and regulatory standards.
  • Reviews and verifies various transactions to ensure accuracy and compliance with Corporate and Legal requirements.
  • Reviews completed documents against system data to ensure accuracy.
  • Interacts with external contacts to coordinate activities related to internal and external audits.
  • Manages inbound communications which may include medical or other types of charts/files, claims, faxes, emails, standard mail, or other related communications and mail correspondence, whether hard copy, voice or electronic.
  • Directs and monitors activities related to sorting, scanning, batching, and indexing documents into the imaging system, including preparation, deletion, rescans, and batch verification.
  • Manages the indexing of scanned documents within the imaging system, ensuring names, account numbers, dates of service, and insurance information are accurately assigned to each batch.
  • Coordinates scanner maintenance and handles return mail and outgoing correspondence, including invoices, statements, appeals, medical record requests, and other documents for the RCM Billing teams.

Enovis develops medical devices and services to improve patient outcomes and restore mobility. It operates Prevention & Recovery with orthopedic braces, soft goods, vascular therapy, compression garments, and hot/cold therapy, and Reconstructive with joint implants and surgical tools such as Novastep. It differentiates itself through a broad clinically oriented portfolio, a global footprint, and the EGX continuous improvement program, plus the LimaCorporate acquisition expanding its transatlantic reach. Its goal is to provide better patient outcomes and mobility worldwide through sustained growth and operational excellence.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • Extremities segment achieves 10% organic growth led by double-digit shoulder gains.
  • ARVIS robot deployment starts with South Africa procedure, adoption expands through 2026.
  • BTIG initiates Buy rating with $41 target on new launches in hips and knees.

What critics are saying

  • $1.18B goodwill impairment from LimaCorporate overpayment erodes R&D capital now.
  • Stryker Mako captures 60% US robotic shoulder procedures, blocks ARVIS adoption by 2027.
  • Zimmer Biomet Persona IQ steals Nebula conversions, slows recon growth by mid-2027.

What makes ENOVIS unique

  • Enovis leverages Enovis Growth Excellence system for continuous operational improvements.
  • Enovis offers ARVIS shoulder robot and Augmented Reverse Glenoid System for extremities.
  • Enovis integrates LimaCorporate acquisition to expand reconstructive implant portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Legal Services

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

32%
Yahoo Finance
Feb 28th, 2026
Enovis reports strong revenue growth and new device uptake despite $1.18B goodwill impairment

Enovis Corporation has reported strong organic revenue growth driven by new product launches, including the Nebula Stem and OrthoDrive Impactor, which have seen rapid market uptake. The medical technology company's devices are gaining traction with surgeons and hospitals. However, Enovis recorded a significant goodwill impairment charge in its fourth quarter and full-year results, affecting its balance sheet. The impairment raises questions about returns from previous acquisitions and future capital allocation strategy. Trading at $25.47, Enovis shares are approximately 44% below the analyst price target of $45.18. The company currently shows a loss of $1.18 billion and trades at a forward price-to-earnings ratio of 25.73 times. Investors are advised to monitor how product adoption and procedure volumes affect future cash flow.

Yahoo Finance
Feb 26th, 2026
Enovis stock jumps 12.6% on strong 2026 earnings forecast despite Q4 revenue miss

Enovis Corporation shares jumped 12.6% in morning trading after the medical technology company reported mixed fourth-quarter results but issued a strong earnings forecast for 2026. Whilst quarterly revenue of approximately $576 million missed expectations, adjusted earnings per share of $0.95 beat analyst estimates. The stock surge was driven by Enovis's 2026 earnings guidance of $3.52 to $3.73 per share, with the midpoint significantly exceeding analyst projections. This positive profit outlook overshadowed the revenue shortfall. Enovis shares have experienced high volatility, with 26 moves exceeding 5% over the past year. The stock is down 6.6% year-to-date and trading 38.1% below its 52-week high of $40 from March 2025.

Yahoo Finance
Feb 26th, 2026
Enovis reports $520.6M Q4 loss despite adjusted earnings of 95 cents per share

Enovis Corporation reported a fourth-quarter loss of $520.6 million, or $9.10 per share. The Wilmington, Delaware-based manufacturing and engineering company posted adjusted earnings of 95 cents per share, excluding asset impairment and non-recurring costs. Revenue for the quarter reached $575.8 million. For the full year, Enovis reported a loss of $1.18 billion, or $20.75 per share, on revenue of $2.25 billion.

Yahoo Finance
Jan 23rd, 2026
BTIG initiates Enovis with $41 target as orthopedic tech firm eyes growth from new product launches

Enovis Corporation has received positive analyst coverage, with BTIG initiating a Buy rating and $41 price target on 6 January. The orthopedic care company is expected to see accelerated growth in 2026 driven by new product launches across extremities, hips and knees. BTIG highlighted the company's consistent mid-to-high single-digit organic revenue growth in its Reconstruction and Prevention & Recovery segments. The higher-growth Reconstruction business is expected to drive margins whilst the mature Prevention & Recovery segment delivers steady cash flow. UBS maintained its Buy rating but lowered its price target to $50 from $57, projecting sales of $2.26 billion in 2025, $2.37 billion in 2026 and $2.52 billion in 2027.

TradingView
Dec 10th, 2025
Enovis secures $700M term loan and $1.1B credit facility, extends maturity to 2030

Enovis Corp has entered Amendment No. 3 to its credit agreement on 8 December, extending the loan maturity date to 8 December 2030. The amended agreement provides a revolving credit facility of up to $1.1 billion and a term loan facility of $700 million. The company used term loan proceeds to repay $335 million from its revolving facility. The amendment restructures Enovis's debt arrangements, providing the medical technology company with extended financing flexibility through the end of the decade.

INACTIVE